A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Mayo Clinic
Corvus Pharmaceuticals, Inc.
Bristol-Myers Squibb
SecuraBio
Alliance for Clinical Trials in Oncology
Dana-Farber Cancer Institute
Fudan University
National Institutes of Health Clinical Center (CC)
Autolus Limited
National Institutes of Health Clinical Center (CC)
Arvinas Inc.
SymBio Pharmaceuticals
M.D. Anderson Cancer Center
Mayo Clinic
Fondazione Italiana Linfomi - ETS
Case Comprehensive Cancer Center
City of Hope Medical Center
SciTech Development, Inc.
Barbara Ann Karmanos Cancer Institute
City of Hope Medical Center
City of Hope Medical Center
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Washington University School of Medicine
BeiGene
Northwestern University
Wake Forest University Health Sciences
Stanford University
University of Nebraska
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Northwestern University
University of Nebraska
University of Nebraska
Canadian Cancer Trials Group
City of Hope Medical Center
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
The First Hospital of Jilin University
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Zhejiang University
Northwestern University
Northwestern University
Roswell Park Cancer Institute
Universität des Saarlandes
Fred Hutchinson Cancer Center
Celgene
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Barbara Ann Karmanos Cancer Institute